CDKN2A and cancer: Interestingly, other studies have also observed this same contradiction [20], and in fact, have noted a distinct inverse relationship between cyclin D1[20,46,47] and p16[20,48,49] levels with poorer clinical outcome, a more aggressive cancer phenotype, and resistance to multiple chemotherapeutic agents.